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Abstract: Acrylamide has been studied for its carcinogenicity in experimental animals, causing tumors
at several organ sites, and has been considered probably carcinogenic to humans as well. Given the
small number of epidemiological studies that have been conducted, it is still uncertain whether the
consumption of acrylamide is associated with liver cancer. Therefore, we investigated a study to
determine the possible relationship between acrylamide intake and the risk of developing liver cancer
in the Japanese population. A total of 85,305 participants, from the Japan Public Health Center-based
Prospective Study, who provided a validated food-frequency questionnaire were enrolled between
1995 and 1998. During a median of 16.0 years follow-up, 744 new liver cancer cases were identified.
Compared to the lowest tertile of acrylamide consumption (<4.8 µg/day), the multivariate hazard ratio
(HR) for the highest tertile (≥7.6 µg/day) was 0.79 (95% confidence interval [CI] = 0.65–0.95) for liver
cancer using multivariable model 1, adjusted for smoking status, body mass index (BMI), physical
activity, medical history, and alcohol consumption; whereas the inverse relationship disappeared
after additionally adjusting for coffee consumption in multivariable model 2 with HR of 1.08 (95% CI
= 0.87–1.34) for the highest tertile. The effect of dietary acrylamide intake on the risk of liver cancer
was not observed in the Japanese population.
Keywords: acrylamide; liver cancer; diet; cohort
1. Introduction
Acrylamide is considered to be a potent neurotoxin agent and has been hypothesized to promote
cancer risk in humans and animals, which particularly occurs via occupational exposure [1–3]. In 1994,
the International Agency for Research on Cancer classified acrylamide as a probable human carcinogen
(Group 2A) [4]. In 2002, a report from Sweden which indicated that acrylamide could be detected in
carbohydrate-rich foods because of high temperature cooking over 120 degree Celsius, was aware of
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the concern of the harmful effects of acrylamide [5]. The formation of acrylamide depends on different
cooking methods, which leads to a wide variability of acrylamide levels in the same food [6].
In western countries, although some epidemiological studies have been investigated into the
effect of acrylamide consumption on the risk of cancers, the results from studies into breast cancer,
endometrial cancer, rectal cancer, and lung cancer were inconsistent [7]. Currently, there are few
epidemiological studies being conducted to determine the relationship between acrylamide intake
from daily diet and the risk of human cancers in Asian countries. One of the reasons for this is that an
appropriate method of estimating acrylamide intake has not been well-established yet. Furthermore,
to our knowledge, the relationship between acrylamide consumption and liver cancer risk has not yet
been investigated anywhere in the world.
The underlying mechanism of promoting the effect of acrylamide on cancers in human beings
is still obscure. Although sufficient evidence from both animal experiments and epidemiological
studies in humans is lacking, it has been reported that one of the pathways for acrylamide metabolism
involves the process of acrylamide being converted to glycidamide, a genotoxic and mutagenic
substance. This conversion occurs in the liver and is mediated by cytochrome P450 2E1 (CYP2E1) [8–10].
In consequence, CYP2E1 has been found to catalyze the bioactivation of some protoxins and
procarcinogens, including N-nitrosodimethylamine. Exposure to N-nitrosodimethylamine has been
known to develop tumors in the lung, kidney, and liver in animals [11,12]. Therefore, it is important
to demonstrate the effect of acrylamide on the human liver. We conducted this study to investigate
whether increasing the dietary intake of acrylamide is related to the risk of developing liver cancer in
the Japanese population. To the best of our knowledge, our study is the first epidemiological study
focusing on this issue.
2. Materials and Methods
2.1. Study Design and Population
The Japan Public Health Center-based Prospective Study (JPHC Study) is a prospective cohort
study, established with the primary aim of establishing evidence to benefit health maintenance and
improvement, including cancer prevention. Between 1990 and 1993 140,420 middle-aged Japanese
adults were recruited as the target population in the JPHC Study. A self-completion questionnaire
survey on lifestyle habits, including dietary habits, was conducted among the study population.
Further, they were requested to provide blood samples and the results of prior local or workplace
health check-ups. All cohort participants were followed up to obtain data regarding the incidence
of death, migration, cancer, and cardiovascular disease. The five-year follow-up survey consisted
of a second questionnaire survey among the cohort participants, being held between 1995 and 1998.
We included all responders of the five-year follow-up survey, and who fulfilled the following criteria:
age between 45 and 74 years old, Japanese nationality, and not registered at any age-biased designated
areas [13]. A total of 93,835 men and women were enrolled into the present cohort. All subjects gave
their informed consent for inclusion before they participated in the study. The study was conducted
in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional
Review Board of the National Cancer Center, Japan (Ethical Approval Code: 2001-021), as well as
Osaka University (Ethical Approval Code: 14020-9) and Azabu University (Ethical Approval Code:
2457).
Of the initial 93,835 participants, we excluded 2989 participants who had been previously
diagnosed with any cancers by the beginning of follow-up. In addition, 26 participants who were lost
to follow-up were excluded from the analysis. Furthermore, we excluded 5515 participants who did
not provide complete dietary data, as a result of which the total energy intake could not be calculated,
and who were identified as the extreme low- and high-energy reporters. After excluding these ineligible
participants, 85,305 participants were analyzed in the present study. (Figure 1)
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Figure 1. Flow diagram of eligibility for an lysis. a Participants only at the age of 40 yrs. And 50 yrs.
old receiv d baseline questionnaire in these areas.
2.2. Acrylamide Intake Assessment
In the JPHC Study, the detailed information on lifestyle habits, history of health status, basic social
factors, and daily dietary habits were obtained through a comprehensive questionnaire, including a
food frequency questionnaire (FFQ). Participants were asked to report the general average consumption
frequency of 138 food and beverage items, of standard portion size, in the last year [14]. The details of
response choices for frequency, standard portion size, and relative portion sizes have been described
elsewhere [15–17]. The validity and reproducibility study of the FFQ has been conducted by taking the
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dietary intakes from 28-day weighed dietary records (DRs) as a reference in a subcohort of the JPHC
Study [18–20]. Moreover, the daily nutrients intake was calculated in reference to the Standard Tables
of Food Composition in Japan (5th revised and enlarged edition) [21].
The acrylamide intake assessment from daily diet was estimated by using the measured values of
acrylamide content in the following common Japanese food and beverage items as follows: baked
fish paste, bread, rice cakes, Japanese-style confectionary, cakes, biscuits and cookies, chocolate,
peanuts, fried tofu, miso, beer, green tea, oolong tea, black tea, coffee, and soup [22–28]. Furthermore,
we estimated the acrylamide content by considering the different cooking methods involved. The intake
of acrylamide from heated starchy vegetables (potato and sweet potato), vegetables (onion, bean
sprouts, sweet pepper, squash, cabbage, snap beans, and broccoli), toast, boiled or stir-fried rice,
and fried batter was calculated by multiplying the amount of raw food by the proportion of heated
food (as calculated from the DRs) and the concentration of acrylamide in each heated food. The validity
and reproducibility of the acrylamide intake assessment were evaluated, and showed Spearman’s
correlation coefficients of 0.34–0.47 reported in detail elsewhere [29].
2.3. Statistical Analysis
Participants contributed person-years from the five-year follow-up survey until the date of
diagnosis of liver cancer, death (from any cause), moving out of study areas, or 31 December 2013,
whichever occurred first. Acrylamide intake was included in the multivariable-adjusted models as a
categorical variable as well as a continuous variable (per 10 µg/day), to investigate the dose-response
relationship. For acrylamide intake to be modeled as a categorical variable, participants were divided
into tertiles according to their energy-adjusted intakes of acrylamide, which was computed using the
residual method. The groups with the highest and lowest consumption were indicated as T3 and T1,
respectively. Patient characteristics at the five-year follow-up survey were compared between groups,
using the Kruskal−Wallis test or Chi-square test, whichever was appropriate. A Cox proportional
hazards regression model was used to estimate hazard ratios (HRs) and their corresponding 95%
confidence intervals (CIs), with T1 as the reference group.
In order to assess potential confounding, besides sex, 5-year age group, and public health center
area, the following variables were tested, based on the previous studies: smoking status (never, former,
current, or missing), body mass index (14 to <19, 19 to <21, 21 to <23, 23 to <25, 25 to <27, 27 to <30,
and 30 to 40 kg/m2, or missing), physical activity (quartiles of metabolic equivalents, or missing),
alcohol consumption (nondrinker, <150 or ≥150 g/week, or missing), and self-reported hepatitis
and diabetes mellitus (reported at the baseline survey and five-year follow-up survey) (no or yes).
The hazard ratio of acrylamide intake in the multivariable-adjusted model 1 was modified using these
variables. Since the previous JPHC Study, coffee consumption has been related with a lower risk of
liver cancer [30]; therefore, coffee consumption (g/day; nondrinker or quintiles) was added to the above
variables in the multivariable-adjusted model 2. We additionally implemented analysis stratified by
coffee consumption (nondrinker and coffee drinker).
Smoking is considered as one of major sources of acrylamide exposure, and smokers have been
found to have a high-level of acrylamide-hemoglobin adducts (which is a marker of the internal dose
of acrylamide) that are, on an average, three to four times higher than that seen in nonsmokers [31].
Consequently, to preclude confounding through smoking status, stratification analysis was performed
according to never and ever smokers.
We also used multivariable-adjusted Cox proportional hazards regression to perform sensitivity
analysis by excluding participants diagnosed with liver cancer within three years of the five-year
follow-up survey (n = 69), and to perform another sensitivity analysis by excluding participants who
reported a history of hepatitis (n = 1762). Furthermore, we conducted the analysis by gender to confirm
whether there were any gender differences. All p-values were two-tailed. P-values less than 0.05 were
considered statistically significant. We performed all the statistical analyses by using Stata/MP 14.1
(StataCorp, College Station, TX, USA).
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3. Results
The distribution of characteristics for participants at 5-year study survey are shown in Table 1.
After adjusting for total energy intake, the mean intake (±SD) of acrylamide by our study population
was 6.9 ± 3.8 µg per day. The major food sources of acrylamide in Japan were coffee (27.4%), green tea
(21.6%), potato (11.0%), vegetables (10.8%), and biscuits (10.6%), which were different from western
countries [27,30,31]. Participants who consumed more acrylamide were, on an average, younger,
had lower intake of alcohol, and less likely to have diabetes or hepatitis.
During a total of 1,267,791 person-years of follow-up (14.9 years on average), 744 cases of
liver cancer were ascertained among the 85,305 eligible participants. Table 2 shows that the higher
energy-adjusted acrylamide intake was associated with a significantly lower risk of liver cancer in the
age- and area-adjusted model and the multivariable model 1. Subjects with a high acrylamide intake
(T3) had a 21% lower liver cancer risk than those who had a low acrylamide intake (T1) (HR = 0.79;
95% CI = 0.65–0.95; P trend = 0.01) in model 1. Results were similar in sensitivity analyses. However,
the statistically significant decrease disappeared after additional adjustment for coffee consumption
(HR = 1.08; 95% CI = 0.87–1.34). Exclusion of cases where liver cancer was diagnosed during the first
three years of follow-up did not change the results in model 2. In addition, the negative result found in
model 2 did not change after considering the information on hepatitis B and C virus infection. Besides,
exclusion of participants who reported a history of hepatitis did not change the results in multivariable
model 3.
Similar results were observed in the stratification analysis by coffee intake. Although an increased
acrylamide intake reduced the risk of liver cancer among coffee drinkers in the multivariable model 1
(HR = 0.74; 95% CI = 0.58–0.94; P trend = 0.01), the inverse association disappeared after additional
adjustment in the multivariable model 2 (HR = 1.05; 95% CI = 0.80–1.38). The association between
acrylamide intake and liver cancer risk was not observed in either the nondrinkers or the coffee drinkers
after considering the amounts of coffee consumption. We did not observe significant differences
between never or ever smokers regarding the association of acrylamide intake with the risk of liver
cancer. Furthermore, no gender differences in HR were observed in the present study, shown in Table 3.
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Table 1. Characteristics of participants (n = 85,305) according to tertile of energy-adjusted acrylamide intake at five-year-study survey.
Characteristics
Tertile of Energy-Adjusted Acrylamide Intake
Tertile 1 Tertile 2 Tertile 3 p-Value c
Number of Participants 28,435 28,435 28,435
Men, % 57.7 44.6 38.4
Dietary variables
Acrylamide intake
Range, µg/d 0.04 − 4.81 4.82 − 7.63 7.64 − 67.11
Mean and SD, a µg /d 3.4 ± 1.0 6.1 ± 0.8 11.1 ± 3.5 <0.001
Mean and SD, a µg·kg
body weight−1·d−1 0.06 ± 0.05 0.11 ± 0.09 0.21 ± 0.23 <0.001
Coffee, a g/d 42.0 ± 57.8 107.1 ± 105.4 276.5 ± 283.8 <0.001
Green tea, a g/d 313.9 ± 337.9 510.7 ± 423.1 764.4 ± 680.8 <0.001
Alcohol intake, a g/d 155.1 ± 241.7 92.2 ± 179.2 58.5 ± 134.2 <0.001
Biscuits, a g/d 0.8 ± 1.2 2.0 ± 2.5 5.0 ± 7.9 <0.001
Potato, a g/d 10.2 ± 9.6 17.8 ± 14.8 21.5 ± 24.0 <0.001
Vegetables, a g/d 180.4 ± 119.8 220.9 ± 128.4 231.1 ± 143.3 <0.001
Fruit, a g/d 178.9 ± 161.4 219.8 ± 163.0 221.1 ± 168.5 <0.001
Meat, a g/d 58.1 ± 43.5 57.1 ± 36.6 56.2 ± 35.6 <0.001
Fish, a g/d 85.9 ± 56.1 88.4 ± 48.9 83.7 ± 47.9 <0.001
Total energy intake, a kcal/d 1997.1 ± 641.5 2019.3 ± 610.4 1971.3 ± 610.1 <0.001
Nondietary variables
Age at 5-year follow-up study, a y 57.8 ± 7.6 57.1 ± 7.9 55.9 ± 8.0 <0.001
Body mass index, a b kg/m2 23.7 ± 3.1 23.6 ± 3.0 23.4 ± 3.0 <0.001
Smoking status, %
Never 57.9 64.8 64.2
<0.001
Former 10.6 8.3 6.8
Current 25.1 21.1 23.3
Missing 6.4 5.8 5.7
Number of cigarettes/d, a b only for current 20.5 ± 14.3 21.2 ± 11.9 22.7 ± 11.4 <0.001
Physical activity (METs) a 33.2 ± 6.4 33.2 ± 6.2 33.1 ± 6.1 <0.001
Diabetes, % yes 8.3 6.6 5.4 <0.001
Hepatitis, % yes 2.4 2.1 1.7 <0.001
a Mean ± s.d. b Number of participants missing the following: body mass index: 2163; number of cigarettes per day for current smokers: 378; physical activity: 15,446. c Kruskal−Wallis
test for continuous variables and Chi-square test for categorical variables.
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Table 2. Hazard ratios (95% confidence intervals) for liver cancer according to tertile of acrylamide intake.
Quartile of Energy-Adjusted Acrylamide Intake
10 µg/d Tertile 1 (Lowest) Tertile 2 Tertile 3 (Highest)
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) p for Trend
Number of subjects 85,305 28,435 28,435 28,435
Person-years 1,267,791 417,202 425,177 425,412
Number of liver cancers 744 311 248 185
Age- and area-adjusted model a 0.96 (0.94–0.98) 1.00 (Reference) 0.88 (0.74–1.04) 0.73 (0.60–0.88) <0.01
Multivariable model 1 b 0.96 (0.94–0.99) 1.00 (Reference) 0.90 (0.76–1.06) 0.79 (0.65–0.95) 0.01
Multivariable model 1 (excluding cases < 3 years) 0.97 (0.94–0.99) 1.00 (Reference) 0.91 (0.76–1.10) 0.82 (0.66–1.01) 0.06
Multivariable model 2 c 0.99 (0.96–1.01) 1.00 (Reference) 1.00 (0.84–1.20) 1.08 (0.87–1.34) 0.51
Multivariable model 2 (excluding cases < 3 years) 0.99 (0.96–1.01) 1.00 (Reference) 0.99 (0.81–1.21) 1.08 (0.85–1.37) 0.58
Multivariable model 3 d (excluding cases with history of hepatitis) 0.99 (0.96–1.02) 1.00 (Reference) 0.95 (0.76–1.18) 1.12 (0.87–1.45) 0.47
By smoking status
Never smoker
Number of subjects 53,137 16,460 18,429 18,248
Person-years 817,862 252,425 283,953 281,484
Number of liver cancers 335 131 109 95
Multivariable model 1 0.98 (0.94–1.01) 1.00 (Reference) 0.86 (0.66–1.11) 0.93 (0.70–1.22) 0.54
Multivariable model 2 0.99 (0.95–1.02) 1.00 (Reference) 0.95 (0.72–1.25) 1.15 (0.85–1.56) 0.42
Ever smoker e
Number of subjects 27,083 10,150 8365 8568
Person-years 382,550 141,189 119,153 122,209
Number of liver cancers 352 147 128 77
Multivariable model 1 0.95 (0.92–0.99) 1.00 (Reference) 1.06 (0.83–1.35) 0.71 (0.53–0.94) 0.03
Multivariable model 2 0.99 (0.95–1.02) 1.00 (Reference) 1.17 (0.90–1.51) 1.07 (0.77–1.51) 0.52
By coffee consumption
Nondrinker
Number of subjects 23,104 13,603 6048 3453
Acrylamide intake (mean ± SD, µg/d) 3.0 ±1.1 6.0 ±0.8 10.8 ±3.1
Acrylamide intake (range, µg/d) 0.0 −4.8 4.8 −7.6 7.6 −67.1
Person-years 335,958 197,392 88,407 50,159
Number of liver cancers 266 160 68 38
Multivariable model 1 1.01 (0.96–1.06) 1.00 (Reference) 1.00 (0.74–1.34) 1.12 (0.77–1.62) 0.63
Drinker
Number of subjects 62,201 14,832 22,387 24,982
Acrylamide intake (mean ± SD, µg/d) 3.7 ±0.8 6.1 ±0.8 11.1 ±3.5
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Table 2. Cont.
Quartile of Energy-Adjusted Acrylamide Intake
10 µg/d Tertile 1 (Lowest) Tertile 2 Tertile 3 (Highest)
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) p for Trend
Acrylamide intake (range, µg/d) 0.4 −4.8 4.8 −7.6 7.6 −62.8
Person-years 931,833 219,810 336,770 375,253
Number of liver cancers 478 151 180 147
Multivariable model 1 0.96 (0.93–0.98) 1.00 (Reference) 0.86 (0.69–1.07) 0.74 (0.58–0.94) 0.01
Multivariable model 2 0.98 (0.95–1.01) 1.00 (Reference) 0.97 (0.77–1.22) 1.05 (0.80–1.38) 0.73
Table 3. Hazard ratios (95% confidence intervals) for liver cancer according to tertile of acrylamide intake by gender.
Quartile of Energy-Adjusted Acrylamide Intake
10 µg/d Tertile 1 (Lowest) Tertile 2 Tertile 3 (Highest)
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) p for Trend
Men
Number of subjects 39,996 16,417 12,669 10,910
Person-years 569,415 231,895 181,770 155,751
Number of liver cancers 530 237 175 118
Age- and area-adjusted model a 0.95 (0.93–0.98) 1.00 (Reference) 0.91 (0.74–1.10) 0.71 (0.57–0.89) <0.01
Multivariable model 1 b 0.96 (0.93–0.99) 1.00 (Reference) 0.94 (0.77–1.14) 0.78 (0.62–0.98) 0.04
Multivariable model 2 c 0.99 (0.96–1.02) 1.00 (Reference) 1.05 (0.85–1.29) 1.15 (0.88–1.50) 0.31
Women
Number of subjects 45,309 12,018 15,766 17,525
Person-years 698,376 185,307 243,407 269,662
Number of liver cancers 214 74 73 67
Age- and area-adjusted model a 0.97 (0.93–1.00) 1.00 (Reference) 0.81 (0.59–1.13) 0.78 (0.56–1.10) 0.16
Multivariable model 1 b 0.97 (0.94–1.01) 1.00 (Reference) 0.76 (0.55–1.06) 0.77 (0.54–1.08) 0.14
Multivariable model 2 c 0.98 (0.95–1.02) 1.00 (Reference) 0.83 (0.59–1.17) 0.92 (0.63–1.32) 0.65
Abbreviations: 95% CI = 95% confidence intervals. a Age- and area-adjusted model adjusted for age (5-year age intervals) and area. b Multivariable model 1 additionally adjusted for:
smoking status (never, former, current, missing), intake of alcohol (nondrinker, <150, ≥150 g/week), body mass index (14−<19, 19−<21, 21−<23, 23−<25, 25−<27, 27−<30, 30–40 kg/m2,
missing), physical activity (quartile, missing), history of diabetes (yes/no), and history of hepatitis (yes/no). c Multivariable model 2 additionally adjusted for: multivariable model 1 and
coffee consumption (nondrinker, quintiles).
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4. Discussion
This large-scale population-based prospective cohort study is, to our knowledge, the first
epidemiological study in humans to demonstrate the association between dietary acrylamide intake
and the risk of liver cancer. We observed no significant association between dietary acrylamide intake
and risk of liver cancer. Although an inverse association was observed in the multivariable model 1,
this association was not observed after further adjustment in the multivariable model 2. These findings
indicate that while coffee drinking may lower the risk of liver cancer, the acrylamide present in coffee
contributes substantially to the total dietary acrylamide intake in Japan. Because of the dichotomic role
of coffee consumption, we interpreted our results based on how coffee affects the risk of liver cancer,
and by distinguishing the effect of acrylamide from the effect of coffee.
Several previous studies have suggested an inverse association between coffee consumption
and liver cancer, both in Japan and in other countries [30,32–35]. Several potential mechanisms
have been proposed through which coffee may lower the risk for developing liver cancer. Coffee is
known to contain a variety of different biologically active chemical compounds including antioxidants
and diterpenes. Antioxidants, for instance caffeine and chlorogenic acids, have been indicated for
preventing oxidative DNA damage, modification effect on the apoptotic response, and reversing the
cell cycle checkpoint function [36–39]. Besides, diterpenes, for instance kahweol and cafestol, have
been shown to have anticarcinogenic properties, and may offer a protective effect against aflatoxin
B1-induced genotoxicity [40–42]. These studies suggest that the ingredients in coffee may play an
important role in protecting against the occurrence and development of liver cancer. Thus, the observed
inverse association in the multivariable model 1, which did not adjust for coffee consumption, could
not indicate the actual effect of dietary acrylamide intake. Because the inverse association disappeared
after additional adjustment for coffee consumption in the multivariable model 2, coffee consumption,
particularly the consumption of caffeine, chlorogenic acids, kahweol, and cafestol, should be considered
as the confounding factor in this study.
To minimize the confounding effect from coffee consumption, stratified analysis was conducted
by comparing HRs in coffee drinkers and nondrinkers. There was no association between acrylamide
intake and liver cancer in nondrinkers. In coffee drinkers, no association was observed after adjustment
for the amount of coffee consumption. These findings suggest that the association of reduced risk of
liver cancer with the high intake of acrylamide was not valid.
The lack of association between acrylamide intake and liver cancer risk could be partly due to
the low baseline range of acrylamide intake used in this study. The mean acrylamide intake for the
reference group in this study was 3.4 µg per day, and for the highest intake category was 11.1 µg
per day. In contrast, in the Netherlands cohort study, the mean acrylamide intake for the reference
group was 9.5 µg per day, and for the highest intake category was 40.8 µg per day [43]. However, it is
important to state that the values of acrylamide intake that were assessed by the FFQ were relative
values. The determination of acrylamide exposure by using hemoglobin adducts as a biomarker of
internal dose is necessary for accurate comparison.
The classification of acrylamide made by the IARC in 1994 was primarily based on evidence from
animal models and mechanistic considerations [4]. In animal models, the dose of acrylamide exposure
was much higher than the doses humans are exposed to through daily diet [44]. Consequently, the dose
of acrylamide exposure differs between experimental animals and epidemiological studies in humans,
and may help to interpret the null finding in the present study.
The present study has several strengths including a large sample size, the population-base and
prospective design, and the completeness of case ascertainment through linkage to the population-based
registries in Japan. However, there are also some limitations that should be discussed. First, the present
study has some limitations regarding acrylamide intake assessment. The FFQ consists of a finite list of
foods and beverages. Therefore, it may be a less accurate estimation of dietary intake when compared
to a 24-h recall method. The correlation for acrylamide intake between the FFQ and the 28-day dietary
records was relatively low [45]. Even though the use of FFQ has limitations in the assessment of dietary
Nutrients 2020, 12, 2503 10 of 12
acrylamide exposure, it is the only feasible way of assessing dietary acrylamide intake over a long
period of time in a large study population. Second, the participants were not divided into more groups
based on dietary acrylamide intake because of the limited number of cases. Likewise, the associations
between dietary acrylamide intake and liver cancer in never smokers and in noncoffee drinkers were
based on analyses with a small number of cases. Third, in the present analysis, both acrylamide intake
and information on covariates had only been measured once, while, it is highly possible that the
participants may change their acrylamide consumption levels during the relatively long follow-up
period. Therefore, these results should be interpreted cautiously.
5. Conclusions
In conclusion, the results of the present study indicate that there was no association between
dietary intake of acrylamide and risk of liver cancer. Further studies with biomarkers of the internal
dose of acrylamide are needed to investigate the carcinogenicity of acrylamide in humans.
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